{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137044721372672.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.3390/md13085016"}},{"identifier":{"@type":"URI","@value":"https://www.mdpi.com/1660-3397/13/8/5016/pdf"}}],"dc:title":[{"@value":"Eribulin in Cancer Treatment"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Halichondrin B is a complex, natural, polyether macrolide derived from marine sponges. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of Halichondrin B. Eribulin was approved by United States Food and Drug Administration in 2010 as a third-line therapy for metastatic breast cancer patients who have previously been treated with an anthracycline and a taxane. It has a unique microtubule dynamics inhibitory action. Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the available information on eribulin with respect to its clinical pharmacology, pharmacokinetics, pharmacodynamics, mechanism of action, metabolism, preclinical studies, and with special focus on clinical trials.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137044721372674","@type":"Researcher","foaf:name":[{"@value":"Umang Swami"}],"jpcoar:affiliationName":[{"@value":"University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044721372673","@type":"Researcher","foaf:name":[{"@value":"Umang Shah"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044721372672","@type":"Researcher","foaf:name":[{"@value":"Sanjay Goel"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 1695 Eastchester Road, Bronx, NY 10461, USA"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"16603397"}],"prism:publicationName":[{"@value":"Marine Drugs"}],"dc:publisher":[{"@value":"MDPI AG"}],"prism:publicationDate":"2015-08-07","prism:volume":"13","prism:number":"8","prism:startingPage":"5016","prism:endingPage":"5058"},"reviewed":"false","dc:rights":["https://creativecommons.org/licenses/by/4.0/"],"url":[{"@id":"https://www.mdpi.com/1660-3397/13/8/5016/pdf"}],"createdAt":"2015-08-07","modifiedAt":"2025-10-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233122368768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comprehensive Structure–Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004238273300224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Low-dose eribulin reduces lung metastasis of osteosarcoma <i>in vitro</i> and <i>in vivo</i>"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186311966336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Class III <i>β</i>-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861288402801792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Synthesis of 11C-Radiolabeled Eribulin as a Companion Diagnostics PET Tracer for Brain Glioblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361412893257078144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694369425488000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694370350974208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204275360896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"悪性軟部腫瘍に対するエリブリンメシル酸塩（ハラヴェン<sup>®</sup>静注1 mg）の臨床効果と抗腫瘍メカニズムについて"},{"@language":"en","@value":"Clinical benefit of eribulin (Halaven<sup>®</sup>) in the treatment of advanced soft tissue sarcoma patients and the novel anti-tumor mechanisms"},{"@value":"新薬紹介総説 悪性軟部腫瘍に対するエリブリンメシル酸塩(ハラヴェン静注1mg)の臨床効果と抗腫瘍メカニズムについて"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ アクセイナンブ シュヨウ ニ タイスル エリブリンメシル サンエン(ハラヴェン ジョウチュウ 1mg)ノ リンショウ コウカ ト コウシュヨウ メカニズム ニ ツイテ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.3390/md13085016"},{"@type":"CROSSREF","@value":"10.18632/oncotarget.26536_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1155/2018/8987568_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20220335_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1038/s41598-019-42300-z_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1093/jjco/hyz096_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1111/cas.14067_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1254/fpj.148.329_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"},{"@type":"CROSSREF","@value":"10.1021/acs.chemrev.9b00063_references_DOI_PAqtC8BXMUJwKVhItAuGfHTj0fi"}]}